Abstract

Multiple factors likely impact response and remission rates in the treatment of depression with repetitive transcranial magnetic stimulation (rTMS). Notably, the role of symptom severity in outcomes with rTMS is poorly understood. This study investigated the predictors of achieving remission in patients suffering from depression who receive ≥3 rTMS treatments per week. Available data on 41 patients treated at Walter Reed National Military Medical Center from 2009 to 2014 were included for analysis. Patients received a range of pulse sequences from 3,000 to 5,000 with left-sided or bilateral coil placement. Primary outcome measures were total score on the Patient Health Questionnaire-9 or the Quick Inventory of Depressive Symptomatology-Self Rated. Remission was defined as a total score less than five, and response was defined as a 50% decrease in the total score on both outcome metrics. Outcomes in patients diagnosed as suffering from mild or moderate depression were compared to those suffering from severe depression. Of the 41 patients receiving treatment, 16 reached remission and 18 reached response by the end of treatment. Remission rate was associated with the initial severity of depression, with patients with mild or moderate depression reaching remission at a significantly higher rate than those with severe depression. Total number of rTMS sessions or length of treatment was not predictors of remission. Patients with a baseline level of depression characterized as mild or moderate had significantly better outcomes following rTMS compared to patients with severe depression.

Highlights

  • In October 2008, the U.S Food and Drug Administration (FDA) cleared the use of repetitive transcranial magnetic stimulation for the acute treatment of major depression

  • Objective/hypothesis: This study investigated the predictors of achieving remission in patients suffering from depression who receive ≥3 repetitive transcranial magnetic stimulation (rTMS) treatments per week

  • We included all patients (N = 70) previously treated for depression with rTMS at Walter Reed National Military Medical Center (WRNMMC) between March 2009 and February 2014 whose data were retained within the patient data management system (PDMS)

Read more

Summary

Introduction

In October 2008, the U.S Food and Drug Administration (FDA) cleared the use of repetitive transcranial magnetic stimulation (rTMS) for the acute treatment of major depression. Since FDA approval, several subsequent studies have supported the findings of efficacy of rTMS in treating depression. In a non-industry supported study, George et al [4] reported similar findings that further substantiate the use of rTMS for treatment of depression [4]. A meta-analysis of 18 good or fair quality studies investigating the use of rTMS for treatment-resistant depression reported that rTMS is a reasonable, effective consideration [5]. Multiple factors likely impact response and remission rates in the treatment of depression with repetitive transcranial magnetic stimulation (rTMS). Reviewed by: Paul Croarkin, Mayo Clinic, USA Daniel Blumberger, Centre for Addiction and Mental Health, Canada.

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.